{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:19:54Z","timestamp":1783059594586,"version":"3.54.6"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Many oncology drugs are approved by the Food and Drug Administration (FDA) based on interim analyses from randomized controlled trials (RCTs) using immature efficacy data. Although expedited approvals expedite access, they create uncertainty about the durability of benefit and long-term efficacy. We aimed to systematically compare initial and updated results from RCTs supporting FDA oncology approvals, evaluating longitudinal changes in relative efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All phase II\u2013III RCTs supporting FDA oncology drug approvals from 2006\u20132025 that reported both initial and updated results were included. Relative efficacy (overall survival [OS] and progression-\/event-free survival [PFS\/EFS]) between groups was quantified using restricted mean survival time (RMST) ratio, with changes over time expressed as Ratio of updated-to-initial RMST ratio (RR). Meta-analyses and meta-regressions were used to estimate pooled effects and identify trial-level factors. Multiple sensitivity analyses, including those based on RMST difference (RMSD), were conducted to assess robustness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 165 RCTs were included. For OS, mean RR was 1.052 (95% CI, 1.029\u20131.063) and meta-analytic RR 1.023 (1.015\u20131.031,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 15.5%); for PFS\/EFS, mean RR was 1.131 (1.102\u20131.153) and meta-analytic RR 1.099 (1.078\u20131.121,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 69.2%), indicating significant relative survival improvement for experimental arms as follow-up matured. 84.7% of OS and 92.5% of PFS\/EFS comparisons showed increased RRs. Sensitivity analyses showed normalized RMSDs of 0.072 months\/year (OS) and 0.156 months\/year (PFS\/EFS) in experimental arms. Shorter initial follow-up and less mature control-arm data were associated with greater relative efficacy gains of experimental treatments.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>With extended follow-up, most FDA-approved oncology drugs with available updated data showed more durable survival benefits. Given the inherent selection of trials with publicly available updates and reconstructable survival curves, these findings should not be interpreted as a global validation of FDA approval decisions, but they underscore the need for dynamic, evidence-maturity-based oversight with ongoing reassessment and strengthened post-marketing surveillance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1876451","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:40:51Z","timestamp":1783057251000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Evolution of clinical benefit in cancer trials: comparing pivotal approval data with updated efficacy"],"prefix":"10.3389","volume":"14","author":[{"given":"Dongdong","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Hematology, Hebei Petro China Central Hospital","place":["Langfang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang Fang","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hebei Petro China Central Hospital","place":["Langfang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangpeng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Public Health, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Hebei Petro China Central Hospital","place":["Langfang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1186\/s12916-024-03800-6","article-title":"Strength of clinical evidence supporting the United States Food and Drug Administration accelerated approvals from 2015 to 2022","volume":"22","author":"Zhang","year":"2024","journal-title":"BMC Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jama.2024.2396","article-title":"Clinical benefit and regulatory outcomes of cancer drugs receiving accelerated approval","volume":"331","author":"Liu","year":"2024","journal-title":"JAMA."},{"key":"B3","doi-asserted-by":"publisher","first-page":"114230","DOI":"10.1016\/j.ejca.2024.114230","article-title":"Challenges of estimating treatment effects after a positive interim analysis","volume":"209","author":"Soon","year":"2024","journal-title":"Eur J Cancer."},{"key":"B4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/pst.2062","article-title":"Delayed treatment effects, treatment switching and heterogeneous patient populations: how to design and analyze RCTs in oncology","volume":"20","author":"Ristl","year":"2021","journal-title":"Pharm Stat."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1200\/JCO.2015.64.2488","article-title":"Comparison of treatment effects measured by the hazard ratio and by the ratio of restricted mean survival times in oncology randomized controlled trials","volume":"34","author":"Trinquart","year":"2016","journal-title":"J Clin Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/1471-2288-13-152","article-title":"Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med Res Methodol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s12874-020-01098-5","article-title":"Dynamic RMST curves for survival analysis in clinical trials","volume":"20","author":"Liao","year":"2020","journal-title":"BMC Med Res Methodol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1001\/jamacardio.2017.2922","article-title":"Restricted mean survival time as a measure to interpret clinical trial results","volume":"2","author":"Kim","year":"2017","journal-title":"JAMA Cardiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"pkac007","DOI":"10.1093\/jncics\/pkac007","article-title":"Pitfall in the design and analysis of comparative oncology trials with a time-to-event endpoint and recommendations","volume":"6","author":"McCaw","year":"2022","journal-title":"JNCI Cancer Spectr."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1001\/jamaoncol.2017.2797","article-title":"Interpretability of cancer clinical trial results using restricted mean survival time as an alternative to the hazard ratio","volume":"3","author":"Pak","year":"2017","journal-title":"JAMA Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1002\/ijc.34473","article-title":"The evidence base of US Food and Drug Administration approvals of novel cancer therapies from 2000 to 2020","volume":"152","author":"Gloy","year":"2023","journal-title":"Int J Cancer."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e237110","DOI":"10.6004\/jnccn.2023.7110","article-title":"Breakthrough therapy cancer drugs and indications with FDA approval: development time, innovation, trials, clinical benefit, epidemiology, and price","volume":"22","author":"Michaeli","year":"2024","journal-title":"J Natl Compr Canc Netw."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e073242","DOI":"10.1136\/bmj-2022-073242","article-title":"FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis","volume":"381","author":"Michaeli","year":"2023","journal-title":"BMJ"},{"key":"B14","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S1470-2045(24)00152-9","article-title":"Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis","volume":"25","author":"Naci","year":"2024","journal-title":"Lancet Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.jaad.2012.02.010","article-title":"Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0","volume":"67","author":"Chen","year":"2012","journal-title":"J Am Acad Dermatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med Res Methodol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.critrevonc.2019.04.008","article-title":"Efficacy and safety of combination immunotherapy for malignant solid tumors: a systematic review and meta-analysis","volume":"138","author":"Wei","year":"2019","journal-title":"Crit Rev Oncol Hematol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1002\/sim.4274","article-title":"The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt","volume":"30","author":"Royston","year":"2011","journal-title":"Stat Med."},{"key":"B20","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"key":"B21","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/978-1-4757-3466-9_16","article-title":"\u201cMeta-analysis of clinical trials,\u201d","author":"O'Rourke","year":"2001","journal-title":"Applied Statistics in the Pharmaceutical Industry"},{"key":"B22","volume-title":"Statistical Methods for Social Scientists","author":"Hanushek","year":"2013"},{"key":"B23","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s11135-006-9018-6","article-title":"A caution regarding rules of thumb for variance inflation factors","volume":"41","author":"O'brien","year":"2007","journal-title":"Qual Quant."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1161\/CIRCULATIONAHA.119.040680","article-title":"Using the restricted mean survival time difference as an alternative to the hazard ratio for analyzing clinical cardiovascular studies","volume":"140","author":"McCaw","year":"2019","journal-title":"Circulation"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e2403490121","DOI":"10.1073\/pnas.2403490121","article-title":"Heterogeneity in effect size estimates","volume":"121","author":"Holzmeister","year":"2024","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e171029","DOI":"10.1001\/jamaoncol.2017.1029","article-title":"Milestone analyses of immune checkpoint inhibitors, targeted therapy, and conventional therapy in metastatic non-small cell lung cancer trials: a meta-analysis","volume":"3","author":"Blumenthal","year":"2017","journal-title":"JAMA Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"djv156","DOI":"10.1093\/jnci\/djv156","article-title":"Milestone survival: a potential intermediate endpoint for immune checkpoint inhibitors","volume":"107","author":"Chen","year":"2015","journal-title":"J Natl Cancer Inst."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.21037\/tlcr-2024-1204","article-title":"Combination of immune checkpoint inhibitors with multi-targeted tyrosine kinase inhibitors for second- or later-line therapy of non-small cell lung cancer: a systematic review and meta-analysis","volume":"14","author":"Xu","year":"2025","journal-title":"Transl Lung Cancer Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1002\/cmdc.202100166","article-title":"Next-generation kinase inhibitors targeting specific biomarkers in non-small cell lung cancer (NSCLC): a recent overview","volume":"16","author":"Das","year":"2021","journal-title":"ChemMedChem."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e002459","DOI":"10.1136\/jitc-2021-002459","article-title":"Systematic review of combinations of targeted or immunotherapy in advanced solid tumors","volume":"9","author":"Tan","year":"2021","journal-title":"J Immunother Cancer."},{"key":"B31","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJM198708133170706","article-title":"Statistical problems in the reporting of clinical trials. A survey of three medical journals","volume":"317","author":"Pocock","year":"1987","journal-title":"N Engl J Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1001\/jamaoncol.2015.4345","article-title":"Medians and milestones in describing the path to cancer cures: telling \u201ctails","volume":"2","author":"Hellmann","year":"2016"},{"key":"B33","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrd.2016.3","article-title":"Combination therapies in oncology","volume":"15","author":"Webster","year":"2016","journal-title":"Nat Rev Drug Discov."},{"key":"B34","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1200\/JOP.18.00005","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline summary","volume":"14","author":"Brahmer","year":"2018","journal-title":"J Oncol Pract."},{"key":"B35","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000194949","article-title":"Molecular targeted therapies for solid tumors: management of side effects","volume":"32","author":"Gr\u00fcnwald","year":"2009","journal-title":"Onkologie"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1876451\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:40:52Z","timestamp":1783057252000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1876451\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":35,"alternative-id":["10.3389\/fpubh.2026.1876451"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1876451","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"article-number":"1876451"}}